Compounds > methyl-o-succinyl-alanyl-alanyl-prolyl-borovaline-pinacol
Page last updated: 2024-11-11

methyl-o-succinyl-alanyl-alanyl-prolyl-borovaline-pinacol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methyl-O-succinyl-alanyl-alanyl-prolyl-borovaline-pinacol: peptide boronic acid inhibitor of pancreatic & leukocyte elastase; RN given refers to all-(L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5487930
MeSH IDM0139360

Synonyms (9)

Synonym
boroval
methyl 4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propyl]pyrrolidine-2-carbonyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoate
aapbv
meosuc-ala-ala-pro-boroval-pinacol
94242-92-9
l-prolinamide, n-(4-methoxy-1,4-dioxobutyl)-l-alanyl-l-alanyl-n-(2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propyl)-
methyl-o-succinyl-alanyl-alanyl-prolyl-borovaline-pinacol
n-(1-hydroxy-1-{[1-hydroxy-1-({1-[2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propyl]prolyl}imino)propan-2-yl]imino}propan-2-yl)-4-methoxy-4-oxobutanimidic acid
DTXSID20915945

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Irreversible inhibitors are effective in a dose-response manner."( The specific treatment of emphysema.
Lucey, EC; Snider, GL; Stone, PJ, 1990)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's4 (66.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.54 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
elastin
[no description available]		3.4820oligopeptide
ConditionIndicatedRelationship StrengthStudiesTrials
Centriacinar Emphysema
[description not available]		05.1941
Bleeding
[description not available]		01.9710
Disease, Pulmonary
[description not available]		02.3720
Hemorrhage
Bleeding or escape of blood from a vessel.		01.9710
Lung Diseases
Pathological processes involving any part of the LUNG.		02.3720